Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThermoDox plus standardized radiofrequency ablation versus standardized radiofrequency ablation alone in hepatocellular carcinoma
2014-000934-53Phase 3Terminated
- Sponsor
- Imunon, Inc.
- Start
- Sep 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doxorubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Imunon, Inc. Primary endpoint: Overall survival. Started Sep 2014; status: terminated.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2014-000934-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000934-53.